# Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

> **NCT03224767** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 24 (actual)

## Conditions studied

- BRAF V600E Mutation Present
- Papillary Craniopharyngioma

## Interventions

- **DRUG:** Vemurafenib
- **DRUG:** Cobimetinib
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT03224767
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-05
- **Primary completion:** 2026-10-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03224767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03224767, "Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03224767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*